Inhaler

216700/2

Inhaler

Field of the Invention

This invention relates to an inhaler for delivering medication to a patient, and more particularly to a metered-dose inhaler.

Background to the Invention

Inhalers for delivering medicament to a patient by inhalation are known. US patent application, publication No. 2006/0076010 discloses an inhaler including a mouthpiece having an outer surface containing at least one longitudinally-extending disuniformity such that when the patient orally engages the mouthpiece at least one void space is created between the outer surface of the mouthpiece and the oral cavity of the patient so as to provide an air flow channel. International patent application, publication No. WO 2007/107160 discloses an inhaler having a flow channel shaped essentially as a tube which is closed in one end by a wall having one or more holes and comprises, close to the end wall, an evenly distributed air inlet which enables air to flow radially towards the holes. Inhaler devices include metered-dose inhalers (of both pressurised and dry-powder types). Metered-dose inhalers typically comprise a medicament-containing vessel and an actuator housing having a medicament delivery outlet in the form of a mouthpiece or nosepiece.

The medicament-containing vessel may be a pressurized canister containing a mixture of active medicament and propellant. Such canisters are usually formed from a deep-drawn aluminium cup having a crimped lid which carries a metering valve assembly. The metering valve assembly is provided with a protruding valve stem which, in use, is inserted as a tight push fit into a so-called stem block in the actuator housing.

Metered-dose inhalers may either be of the manually operable type or the breath-actuated type. For the manually operable type, the patient self-administers the medicament by manually pressing the closed end of the canister into the actuator housing to cause movement of the canister relative to its valve stem (which is fixed in the stem block of the actuator housing). This movement is sufficient to actuate the metering valve assembly of the canister, resulting in the pressurised contents of a metering chamber being vented through the stem, through the stem block and its exit jet and orifice, and causing the medicament to exit the mouthpiece or nosepiece as an aerosol mist. Simultaneously with this action, the patient inhales through the nosepiece or mouthpiece, entraining the aerosol mist in the inhaled stream of air. The patient then releases the depression force on the canister which, under the action of an internal valve spring, moves upward with respect to the valve stem, returning to its resting position. 1 WO 2010/142418 PCT/EP2010/003426 A more recent development is the so-called breath-actuated metered-dose inhaler, which serves to automatically displace the canister relative to its valve stem and release the contents of the canister's metering chamber in response 5 to a patient's inspiration. The general purpose of such inhalers is to alleviate difficulties in coordinating actuation of the metering valve assembly with the patient's inspiration, and to provide for a maximal amount of medication to be drawn into the patient’s lungs. A breath-actuated metered-dose inhaler is disclosed in WO 01/93933 A2. io

The actuator housing is generally regarded as an integral part of the medicament delivery system, since the design of the housing can greatly affect the form of the medicament generated for inhalation by the patient. The actuator housing of a metered-dose inhaler typically includes an air inlet 15 means for producing an air flow through the actuator housing into which the medicament is released.

Further, for breath-actuated inhalers, the air flow through the actuator housing typically operates or at least influences in some way the breath-actuated 20 mechanism. Consequently, the actuator housing of such inhalers comprises air inlets designed to allow airflow through the housing. However, such air inlets exhibit the problem that they can be covered or occluded by the patient’s hand or finger during use, thereby preventing or influencing the airflow through the actuator housing, with the result that the breath-actuated 25 mechanism may malfunction. This problem is often exacerbated by the fact that the air inlets are provided on the actuator housing at positions which are convenient for handling the inhaler during use by the patient.

Thus, there is a need in the art to provide improved airflow configurations for 30 inhalers that are less susceptible to being occluded or blocked by the patient during use, while at the same time allowing for convenient and comfortable operation by the patient. 2 WO 2010/142418 PCT/EP2010/003426

Summary of the Invention

According to the invention, there is provided an inhaler for delivering medicament to a patient, the inhaler comprising a housing for holding the 5 medicament and having an air inlet means and a medicament delivery port which together define an air flow path into which the medicament is dispensed, wherein the air inlet means comprises an array of elongate apertures formed in the housing, the long sides of adjacent apertures facing each other, 10 and each aperture being provided with a respective different opening in an outer surface of the housing, and wherein the opening of each aperture extends in two different planes such that, if at least a part of the opening is covered in one of the two different planes during inhalation by the patient, a void space is created 15 between the cover and the aperture so as to provide an air flow path through the void space to the at least one aperture.

The inventors have found that the provision of multiple elongate apertures having respective different openings, each extending in two different planes, 20 minimises the risk of the air inlet means becoming blocked. By different openings, it is meant that the opening of each aperture is defined, at least in part, by surfaces which are unique to that opening.

Embodiments of the invention may therefore prevent the air inlet means from 25 being blocked by the patient during use, particularly by the patient’s finger or thumb which each comprise soft tissue and can conform to different surface reliefs. By providing void spaces between the patient and the apertures when the patient covers the air inlet means, a substantial air flow path can be maintained which enables air to flow through the air inlet means despite the 30 air inlet means being covered by the patient.

Embodiments may be particularly advantageous for use in conjunction with metered-dose inhalers, and particularly breath-actuated inhalers of this type containing a pressurised aerosol canister. 3 WO 2010/142418 PCT/EP2010/003426

The invention may be applied to known inhalers with only minimal design changes, thereby reducing the potential for patient confusion, and avoiding large tooling costs that would be associated with more significant design 5 changes.

The apertures of the air inlet means may be arranged to be parallel to one another. In this way, it may be possible to maximise the air flow through an air inlet means having a predetermined cross-sectional area. Raised, 10 elongate formations having the form of ribs may be provided between adjacent apertures to define the different openings of the apertures.

The apertures may have a length in the range 2 mm to 20 mm, preferably in the range 4 mm to 12 mm. The apertures may have a width in the range 0.5 15 mm to 2 mm, preferably about 1 mm. The distance between adjacent apertures may be the same as the width of the apertures. The raised surface formations provided between adjacent apertures may have a height in the range 0.5 mm to 5 mm, preferably 1 mm to 3 mm. 20 In embodiments, each aperture is in effect provided in a respective different recess in the outer surface of the housing, which recess defines the opening of the aperture. The area of the opening of each aperture (in the outer surface of the housing) may be larger than an area of the aperture in the inner surface of the housing, for example the recess may surround the aperture. In 25 general, however, it is preferred that at least one dimension of the recess is the same as, or similar to, the corresponding dimension of the aperture, in order to minimise the risk of the air inlet means becoming blocked.

As mentioned above, it is an essential feature of the invention that the 30 opening of each aperture extends in two different planes, that is to say the opening defines some curvature or an edge between angled planes. In preferred embodiments, the opening of each aperture extends in different planes defining an angle of at least 45 degrees, and more preferably at least 60 degrees, and most preferably at least 80 degrees. 4 WO 2010/142418 PCT/EP2010/003426

The housing may comprise an elongate body, which body may be unitary or multi-part. The air inlet means may conveniently be provided at an end of the elongate body opposite to an end at which the medicament delivery port is 5 provided. In this case, the air inlet means may comprise a pair of the arrays of elongate apertures arranged at opposite sides of the end face of the elongate body, with a raised, elongate surface formation provided between the arrays. to The inhaler may be a metered-dose inhaler, particularly a breath-actuated metered-dose inhaler. The housing may be adapted for receiving a medicament-containing pressurised canister.

Brief description of the drawings 15 An embodiment of the invention will now be described, by way of example only, with reference to the accompanying diagrams, in which:

Figure 1 shows an inhaler having an air inlet means according to the prior art document WO 01/93933 A2;

Figure 2 is an enlarged view of an inhaler having an air inlet means 20 according to an embodiment of the invention; and

Figure 3 is side view of the inhaler shown in Figure 2.

Detailed description

The invention provides an inhaler, such as a breath-actuated pressurised 25 metered-dose inhaler, for delivering medicament to a patient. The inhaler comprises a housing for holding the medicament, and having an air inlet means and a medicament delivery port which together define an air flow path into which the medicament is dispensed. The air inlet means comprises an array of elongate apertures formed in the housing, the long sides of adjacent 30 apertures facing each other. Each aperture is provided with a respective different opening in an outer surface of the housing. The opening of each aperture extends in two different planes such that, if at least a part of the opening is covered in one of the two different planes during inhalation by the 5 WO 2010/142418 PCT/EP2010/003426 patient, a void space is created between the cover and the aperture so as to provide an air flow path through the void space to the at least one aperture.

Referring to Figure 1, there is shown a breath-actuated pressurised metered- 5 dose inhaler 10 having an air inlet means 12 according to the prior art document WO 01/93933 A2 (the entire disclosure of which is incorporated herein by reference). A detailed explanation of the principle of operation of the inhaler 10 is not essential for understanding the invention, but a brief explanation will be provided by way of background information. io

The inhaler 10 comprises a main body 14 and an end cap 16 which together define an elongate actuator housing. The main body 14, which is generally cylindrical in cross-section, is provided with a laterally extending mouthpiece 18 at one end and at the other end is adapted to receive a portion of a 15 cylindrical medicament-containing pressurised canister. A stem block (not shown) is provided within the main body 14 for receiving the valve stem of the canister, and includes an exit jet and orifice communicating with the mouthpiece 18. 20 The end cap 16, which is also generally cylindrical in cross-section, is provided with the air inlet means 12 at one end and at the other end is adapted to receive the remaining portion of the canister. The main body 14 and end cap 16 are connected together by a threaded coupling. Components of the breath-actuated mechanism (not shown) are contained within both the 25 main body 14 and the end cap 16.

The breath-actuated mechanism and canister contained within the housing 14,16 provide one or more air pathways such that air may pass from the air inlet means 12 to the mouthpiece 18 through the inside of the housing 14,16. 30

The mouthpiece 18 is provided with a dust cap 20 rotatable about an axis 22 between a first (closed) position (as shown in Figure 1) and a second (open) position. In use, the patient rotates the dust cap 20 to its open position and inserts the exposed mouthpiece 18 into their mouth. On inhalation by the 6 WO 2010/142418 PCT/EP2010/003426 patient through the mouthpiece 18, a pressure differential in the housing 14,16 causes the breath-actuated mechanism to automatically displace the canister relative to its valve stem. Medicament contained within the metering chamber of the canister is accordingly released in response to the patient's 5 inspiration.

During the patient’s inspiration, air flows from the air inlet means 12, through the housing 14, 16, to the mouthpiece 18, and therefore to the patient. The medicament released from the metering chamber of the canister is entrained io in this airflow.

After inhalation of the dose of medicament by the patient, the dust cap 22 is returned to its closed position, and this causes the breath-activated mechanism and the aerosol canister to reset to a rest position ready for 15 subsequent use.

The air inlet means 12 of the inhaler 10 shown in Figure 1 comprises a plurality of elongate apertures 24 formed in the end face of the end cap 16. The apertures 24 are arranged in a pair of arrays provided on opposite sides 20 of the end face. Although there is a limited amount of three-dimensionality 26 provided between the arrays, the openings of adjacent apertures 24 in each of the arrays define a flat surface. Consequently, in use of the inhaler, it is a problem that the apertures 24 can become blocked by the finger or thumb of the patient, which may lead to a malfunction of the breath-actuated 25 mechanism and/or incomplete or ineffective delivery of the medicament to the patient.

Referring now to Figures 2 and 3, there is shown enlarged view of an inhaler 100 having an air inlet means 102 according to an embodiment of the 30 invention. With the exception of its air inlet means 102, the inhaler 100 according to the invention has the same structure and use as the known inhaler 10 shown in Figure 1. A detailed description of the individual components of the inhaler 100, other than the end cap having the air intake means 102, will accordingly be omitted. Similarly, a detailed description of the 7 WO 2010/142418 PCT/EP2010/003426 use of the inhaler 100 will also be omitted.

The air inlet means 102 of the inhaler 100 comprises a plurality of parallel, elongate apertures 104 having an approximately rectangular shape. The 5 apertures 104 are formed in the end face of the end cap 106. The apertures 104 are arranged in two distinct arrays provided on opposite sides of the end face, each array comprising five apertures 104 whose long sides face one another. Short sides of the apertures 104 in one of the arrays face short sides of the apertures 104 in the other of the arrays, and are separated by a pair of io elongate surface protrusions 108 which extend in a direction perpendicular to the length direction of the apertures 104.

Each of the apertures 104 is effectively recessed in the surface of the end cap 106, and the recess defines an opening of the aperture 104. The recesses 15 are defined by raised, elongate surface protrusions in the form of moulded ribs 110 arranged between the long sides of adjacent apertures 104. Each recess is open at one end, with a corresponding end of each rib 110 being chamfered. As such, the opening of each aperture 104 extends in two substantially perpendicular planes: a horizontal plane corresponding to the 20 “top” portion of the opening and a vertical plane corresponding to the “side” portion of the opening.

The apertures 104 have lengths which vary from 5 mm to 7mm, and a width of 1 mm. A spacing between apertures 104 is 1.2 mm, and the elongate ribs 25 104 filling these spaces have a height of 2.5 mm.

In use of the inhaler 100, if the patient covers at least a part of the openings of the apertures 104 in one of the two different planes, for example with their finger or thumb, then void spaces are created between the patient and the 30 apertures 104 so as to provide an air flow path through the void spaces to the apertures 104, thereby preventing the apertures 104 from being occluded or blocked by the patient.

In other words, if the air inlet means 102 is covered by a surface extending in 8 WO 2010/142418 PCT/EP2010/003426 the horizontal plane which prevents vertical air flow (as illustrated by the arrows labelled “V” in Figures 2 and 3) into the apertures 104, for example, the configuration of the air inlet means 102 is such that the openings of the apertures 104 extend at least partially in the vertical plane enabling horizontal 5 air flow (as illustrated by the arrows labelled “H” in Figures 2 and 3) into the apertures 104. Conversely, if the air inlet means 102 is covered by a surface extending in the vertical plane which prevents horizontal air flow (as illustrated by the arrows labelled “H”) into the apertures 104, the configuration of the air inlet means 102 is such the openings of the holes 24 extend in the horizontal io plane enabling vertical air flow (as illustrated by the arrows labelled “V”) into the apertures 104.

With specific reference to Figure 3, it can be seen that the elongate ribs 110 which define the openings of the apertures 104 stand proud of the 15 surrounding surface 112 of the end cap 106. The elongate ribs 110 thus ensure a void space can be maintained between the patent’s finger or thumb and the apertures 104. A specific embodiment has been described herein for purpose of illustration. 20 Various modifications will be apparent to a person skilled in the art and may be made without departing from the scope of the invention.

For example, although the embodiment described above is implemented as breath-actuated pressurised metered-dose inhaler, it will be understood that 25 alternative embodiments may more generally comprise an inhaler for delivering medication to a patient by inhalation, wherein restriction or prevention of blockage of air inlets by the patient is desirable. Such prevention of blockage may, for example, be desirable in dry-powder inhalers in which a source of air is required for effective atomisation of the 30 medicament.

In the embodiment described above, the air inlet means is arranged in an end face of the end cap. In alternative embodiments the air inlet means may be 9 WO 2010/142418 PCT/EP2010/003426 provided elsewhere, such as in the end face of the main body, adjacent to the mouthpiece.

Components of an inhaler according to the invention will typically be moulded plastics components. Such components can conveniently be provided with the surface features of the invention.

In embodiments the inhaler comprises a medicament-containing pressurised canister containing a medicament and a propellant.

Typically, the medicament is selected from the group consisting of antiinflammatory agents, anti-cholinergic agents, p2-adrenoreceptor agonists, anti-infective agents, anti-histamines and combinations thereof.

Suitable anti-inflammatory agents include corticosteroids and NSAIDs. Suitable corticosteroids which may be used include those oral and inhaled corticosteroids and their pro-drugs which have anti-inflammatory activity. Examples include methyl prednisolone, prednisolone, dexamethasone, fluticasone propionate, 6a, 9a-difluoro-17a-[(2-furanylcarbonyl) oxy] - 11 -hydroxy-16a-methyl-3-oxo-androsta-1, 4-diene-17 -carbothioic acid S-fluoromethyl ester, 6a, 9a-difluoro-11 -hydroxy-16a-methyl-3-oxo-17a-propionyloxy- androsta-1, 4-diene-17p-carbothioic acid S- (2-oxo-tetrahydro-furan-3S-yi) ester, beclomethasone esters (e. g. the 17-propionate ester or the 17,21-dipropionate ester), budesonide, flunisolide, mometasone esters (e. g. the furoate ester), triamcinolone acetonide, rofleponide, ciclesonide, butixocort propionate, RPR- 106541, and ST-126. Preferred corticosteroids include fluticasone propionate, 6a, 9c-difluoro-11 -hydroxy-16a-methyl-17a-[(4-methyl-1, 3-thiazole-5-carbonyl) oxy] - 3-oxo-androsta-1, 4-diene-17, 8-carbothioic acid S-fluoromethyl ester and 6a, 9a- difluoro-17a-[(2- furanylcarbonyl) oxyl-11 -hydroxy-16a-methyl-3-oxo-androsta-1, 4- diene-17p-carbothioic acid S-fluoromethyl ester, more preferably 6a, 9a-difluoro-17a- [(2-furanylcarbonyl) oxy]-11 -hydroxy-16a-methyl-3-oxo-androsta-1, 4-diene-17 -carbothioic acid S-fluoromethyl ester. io WO 2010/142418 PCT/EP2010/003426

Suitable NSAIDs include sodium cromoglycate, nedocromil sodium, phosphodiesterase (PDE) inhibitors (e. g. theophylline, PDE4 inhibitors or mixed PDE3/PDE4 inhibitors), leukotriene antagonists, inhibitors of leukotriene synthesis, iNOS inhibitors, tryptase and elastase inhibitors, beta-2 5 integrin antagonists and adenosine receptor agonists or antagonists (e. g. adenosine 2a agonists), cytokine antagonists (e. g. chemokine antagonists) or inhibitors of cytokine synthesis.

Suitable other p2-adrenoreceptor agonists include salmeterol (e. g. as the io xinafoate), salbutamol (e. g. as the sulphate or the free base), formoterol (e. g. as the fumarate), fenoterol or terbutaline and salts thereof.

Suitable anticholinergic agents are those compounds that act as antagonists at the muscarinic receptor, in particular those compounds, which are 15 antagonists of the M1 and M2 receptors. Compounds include the alkaloid of the belladonna plants as illustrated by the likes of atropine, scopolamine, homatropine, hyoscyamine; these compounds are normally administered as a salt, being tertiary amines. 20 Particularly suitable anticholinergics include ipratropium (e.g. as the bromide), sold under the name Atrovent, oxitropium (e. g. as the bromide) and tiotropium (e. g. as the bromide) (CAS-139404-48-1). Also of interest are: methantheline (CAS-53-46-3), propantheline bromide (CAS-50-34-9), anisotropine methyl bromide or Valpin 50 (CAS-80-50-2), clidinium bromide 25 (Quarzan, CAS-3485-62-9), copyrrolate (Robinul), isopropamide iodide (CAS-71-81-8), mepenzolate bromide (U. S. patent 2,918, 408), tridihexethyl chloride (Pathilone, CAS-4310-35-4), and hexocyclium methylsulfate (Tral, CAS-115-63-9). See also cyclopentolate hydrochloride (CAS-5870-29-1), tropicamide (CAS-1508-75-4), trihexyphenidyl hydrochloride (CAS-144-11-6), 30 pirenzepine (CAS-29868-97-1), telenzepine (CAS-80880-90-9), AF-DX 116, or methoctramine, and the compounds disclosed in W001/04118.

Suitable antihistamines (also referred to as H1-receptor antagonists) include any one or more of the numerous antagonists known which inhibit Μ WO 2010/142418 PCT/EP2010/003426 receptors, and are safe for human use. All are reversible, competitive inhibitors of the interaction of histamine with H1-receptors. Examples include ethanolamines, ethylenediamines, and alkylamines. In addition, other first generation antihistamines include those which can be characterized as based 5 on piperizine and phenothiazines. Second generation antagonists, which are non-sedating, have a similar structure-activity relationship in that they retain the core ethylene group (the alkylamines) or mimic the tertiary amine group with piperizine or piperidine. Exemplary antagonists are as follows; Ethanolamines carbinoxamine maleat, clemastine fumarate, 10 diphenylhydramine hydrochloride, and dimenhydrinate.

Ethylenediamines: pyrilamine amleate, tripelennamine HCI, and tripelennamine citrate. 15 Alkylamines: chlropheniramine and its salts such as the maleate salt, and acrivastine.

Piperazines: hydroxyzine HCI, hydroxyzine pamoate, cyclizine HCI, cyclizine lactate, meclizine HCI, and cetirizine HCI. 20

Piperidines: Astemizole, levocabastine HCI, loratadine or its descarboethoxy analogue, and terfenadine and fexofenadine hydrochloride or another pharmaceutical acceptable salt. 25 Azelastine hydrochloride is yet another H1 receptor antagonist which may be used in combination with a PDE4 inhibitor.

Particularly suitable anti-histamines include methapyrilene and loratadine. 30 Preferably the medicament is presented in a formulation comprising a propellant and preferably a solvent; other preferred ingredients include surfactants, including oleic acid. Preferred solvents include ethanol, glycerols and glycols. 12 WO 2010/142418 PCT/EP2010/003426

Preferred propellants include hydrofluroalkanes; in particular 1,1,1,2-tetrafiuoroethane (HFA134a); 1,1,1,2,3,3,3-Heptafluoropropane (HFA227); or combinations thereof. Preferably, the medicament is suspended in the propellant. Alternatively the medicament is dissolved in the propellant. The 5 medicament may also be part suspended and part dissolved in the propellant.

Examples

The following medicament formulations were used in the inhaler:

Example formulation 1:

Ingredient_Quantity / mg per ml

Beclomethasone dipropionate 1.00 Ethanol 94.80 H FA 134a 1090.20

Example formulation 2: Ingredient Mass / mg Salbutamol sulphate 0.1098 HFA 134a 27.8 Ethanol 3.6 13